Evercore ISI lowered the firm’s price target on Abbott (ABT) to $142 from $144 and keeps an Outperform rating on the shares. The Medtech sector shows promising momentum and the underlying performance, especially in Medical Devices, “signals optimism for the future, even as some headline numbers fell slightly short of expectations,” the analyst tells investors in a post-earnings note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $146 from $141 at Raymond James
- Abbott price target raised to $146 from $142 at Wells Fargo
- Abbott Laboratories: Strong Growth Prospects and Stable Financial Health Drive Buy Rating
- Abbott Laboratories Reports Strong Q3 2025 Earnings
- Abbott Laboratories’ Earnings Call Highlights Strong Growth